| Clinical Laboratory Practices and Quality Control | Lifetime | 6 | AU 1 | 99.20 |
| COVID-19 Clinical Research Studies | Lifetime | 141 | AU 3 | 99.21 |
| Blood groups and transfusion | Lifetime | 59 | AU 1 | 99.21 |
| Platelet Disorders and Treatments | Lifetime | 89 | AU 3 | 99.10 |
| Venous Thromboembolism Diagnosis and Management | Lifetime | 210 | AU 7 | 99.34 |
| Heparin-Induced Thrombocytopenia and Thrombosis | Lifetime | 33 | AU 1 | 98.92 |
| Blood disorders and treatments | Lifetime | 82 | AU 2 | 98.53 |
| Long-Term Effects of COVID-19 | Lifetime | 259 | AU 3 | 97.72 |
| Blood Coagulation and Thrombosis Mechanisms | Lifetime | 151 | AU 2 | 98.73 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 188 | AU 4 | 99.00 |
| Hemophilia Treatment and Research | Lifetime | 64 | AU 1 | 98.82 |
| Intramuscular injections and effects | Lifetime | 13 | AU 2 | 97.83 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 447 | AU 13 | 98.88 |
| Blood properties and coagulation | Lifetime | 137 | AU 2 | 98.34 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 916 | AU 18 | 98.59 |
| Systemic Lupus Erythematosus Research | Lifetime | 432 | AU 4 | 98.64 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | Lifetime | 241 | AU 7 | 97.79 |
| COVID-19 and healthcare impacts | Lifetime | 651 | AU 25 | 93.65 |
| Complement system in diseases | Lifetime | 443 | AU 21 | 96.23 |
| Hemostasis and retained surgical items | Lifetime | 112 | AU 2 | 95.07 |
| Health and Medical Research Impacts | Lifetime | 418 | AU 20 | 92.45 |
| Trauma, Hemostasis, Coagulopathy, Resuscitation | Lifetime | 704 | AU 31 | 93.37 |
| Pharmacovigilance and Adverse Drug Reactions | Lifetime | 311 | AU 11 | 91.95 |
| Blood transfusion and management | Lifetime | 704 | AU 30 | 92.00 |
| Meta-analysis and systematic reviews | Lifetime | 665 | AU 48 | 92.68 |
| Dermatological and COVID-19 studies | Lifetime | 305 | AU 2 | 87.62 |
| Reliability and Agreement in Measurement | Lifetime | 258 | AU 11 | 80.83 |
| Platelet Disorders and Treatments | 2021-2025 | 9 | AU 1 | 99.24 |
| Blood groups and transfusion | 2021-2025 | 10 | AU 1 | 99.23 |
| Venous Thromboembolism Diagnosis and Management | 2021-2025 | 65 | AU 2 | 99.08 |
| Heparin-Induced Thrombocytopenia and Thrombosis | 2021-2025 | 8 | AU 2 | 98.38 |
| Blood Coagulation and Thrombosis Mechanisms | 2021-2025 | 13 | AU 1 | 98.41 |
| COVID-19 Clinical Research Studies | 2021-2025 | 333 | AU 12 | 98.41 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 59 | AU 4 | 98.16 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 133 | AU 2 | 97.68 |
| Complement system in diseases | 2021-2025 | 50 | AU 2 | 96.69 |
| Intramuscular injections and effects | 2021-2025 | 8 | AU 1 | 95.94 |
| Clinical Laboratory Practices and Quality Control | 2021-2025 | 16 | AU 2 | 96.95 |
| Blood properties and coagulation | 2021-2025 | 42 | AU 3 | 93.59 |
| Hemophilia Treatment and Research | 2021-2025 | 78 | AU 2 | 95.81 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | 2021-2025 | 171 | AU 3 | 92.19 |
| Trauma, Hemostasis, Coagulopathy, Resuscitation | 2021-2025 | 239 | AU 12 | 87.75 |
| Blood disorders and treatments | 2021-2025 | 190 | AU 3 | 85.32 |
| Dermatological and COVID-19 studies | 2021-2025 | 114 | AU 2 | 80.97 |
| Meta-analysis and systematic reviews | 2021-2025 | 452 | AU 52 | 81.62 |
